Progestin suppresses matrix metalloproteinase production in endometrial cancer

Gynecologic Oncology

Volumn 89, Issue 2, 2003, Pages 325-333

  Di Nezza, Lisa A ^a,b   Jobling, Tom ^a   Salamonsen, Lois A ^a  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Endometrial carcinoma; Matrix metalloproteinases; Progesterone receptor; Steroid hormones; Tissue inhibitors of metalloproteinases

Indexed keywords

CYTOKINE; ESTRADIOL; GELATINASE A; GELATINASE B; GESTAGEN; GROWTH FACTOR; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR; STEROID HORMONE; STEROID RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CASE REPORT; CELL ISOLATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOMETRIUM CARCINOMA; ENZYMATIC DEGRADATION; ENZYME ASSAY; ENZYME RELEASE; ENZYME REPRESSION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FEMALE; HORMONE ACTION; HUMAN; HUMAN CELL; HYSTERECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; ZYMOGRAPHY;

EID: 0242684745     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00089-1     Document Type: Article

References (39)

1. Barber H.R. Uterine cancer (prevention). Cancer. 47:(5 Suppl.):1981;1126-1132.
2. Bokhman J.V. Two pathogenic types of endometrial carcinoma. Gynecol Oncol. 15:1983;10-17.
3. Deligdisch L., Cohen C.J. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer. 56:1985;1452-1455.
4. Deligdisch L., Holinka C.F. Progesterone receptors in two groups of endometrial carcinoma. Cancer. 57:1986;1385-1388.
5. Nyholm H.C.J., Nielson A.C., Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment comparison of clinical and histopathological characteristics . Gynecol Oncol. 49:1993;229-235.
6. Cohen C.J., Rahaman J. Endometrial cancer. Cancer. 76:1995;2044-2052.
7. Sherman M.E. Theories of endometrial carcinogenesis a multidisciplinary response . Mod Pathol. 13:2000;295-308.
8. Sivridis E., Fox H., Buckley C.H. Endometrial carcinoma two or three entities? Int J Gynecol Cancer. 8:1998;183-188.
9. Arnett-Mansfield R.L., deFazio A., Wain G.V., Jaworski R.C., Byth K., Mote P.A., Clarke C.L. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 61:2001;5476-5482.
10. Kurman R.J. Excessive estrogen in women with grade I adenocarcinoma. Science. 2:(2):1994;2-6.
11. Bokhman J.V., Chepick O.F., Volkova A.T., Vishnevsky A.S. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol. 20:(2):1985;139-155.
12. Kim Y.B., Holschneider C.H., Gosh K., Nieberg R.K., Montz F.J. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer. 79:1997;320-327.
13. Imai M., Jobo T., Sato R., Kawaguchi M., Kuramoto H. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus - usefulness and limitations. Eur J Gynaecol Oncol. 22:(3):2001;217-220.
14. Montz F.J., Bristow R.E., Bovicelli A., Tomacruz R., Kurman R.J. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 186:(4):2002;651-657.
15. Grundker C., Volker P., Schulz K., Emons G. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol. 78:2000;194-202.
16. Lupulescu A. Estrogen use and cancer risk a review . Exp Clin Endocrinol. 101:1993;201-214.
17. Gusberg S.B. Estrogen and endometrial cancer an epilogue . Gynecol Oncol. 52:1994;3-9.
18. Berchuk A., Boyd J. Molecular basis of endometrial cancer. Cancer. 76:1995;2034-2040.
19. Kumar N.S., Richer J., Owen G., Litman E., Horwitz K.B., Leslie K.K. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells implications for unopposed estrogen action . Cancer Res. 58:1998;1860-1865.
20. Woessner J.F. Matrix Metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
21. Edwards D.R., Murphy G. Proteases - invasion and more. Nature. 394:(6693):1998;527-528.
22. Shapiro S.D. Matrix metalloproteinase degradation of extracellular matrix biological consequences . Curr Opin Cell Biol. 10:1998;602-608.
23. Ray J.M., Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J. 7:1994;2062-2072.
24. Di Nezza L.A., Misajon A., Zhang J., Jobling T., Quinn M.A., Ostor A.G., Nie G., Lopata A., Salamonsen L.A. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 94:(5):2002;1466-1475.
25. Fini M.E., Cook J.R., Mohan R., Brinckerhoff C.E. Regulation of matrix metalloproteinase gene expression. Parks W.C., Mecham R.P. Matrix metalloproteinases. 1998;299-356 Academic Press, San Diego.
26. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 17:2001;463-516.
27. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer innovations for the post - trial era . Nature Rev Cancer. 2:2002;657-672.
28. Salamonsen L.A., Woolley D.E. Menstruation induction by matrix metalloproteinases and inflammatory cells . J Reprod Immunol. 44:(1-2):1999;1-27.
29. Zhang J., Hampton A.L., Nie G., Salamonsen L.A. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP enzymes coordinately expressed in human endometrium . Biol Reprod. 62:2000;85-94.
30. Zhang J., Nie G., Wang J., Woolley D.E., Salamonsen L.A. Mast cell regulation of human endometrial matrix metalloproteinases A mechanism underlying menstruation . Biol Reprod. 59:1998;693-703.
31. Salamonsen L.A., Butt A.R., Hammond F.R., Garcia S., Zhang J. Production of endometrial matrix metalloproteinases, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab. 82:1997;1409-1415.
32. Hampton A.L., Butt A.R., Riley S.C., Salamonsen L.A. Tissue inhibitors of metalloproteinases in endometrium of ovariectomized steroid-treated ewes and during the estrous cycle and early pregnancy. Biol Reprod. 53:(2):1995;302-311.
33. Zemer R., Fishman A., Bernheim J., Zimlichman S., Markowicz O., Altaras M., Klein A. Expression of cytokeratin-20 in endometrial carcinoma. Gynecol Oncol. 70:(3):1998;410-413.
34. Ethier S.P. Human breast cancer cell lines as models of growth regulation and disease progression. J Mamm. Gland Biol Neoplasia. 1:(1):1996;111-121.
35. van den Brule F.A., Engel J., Stetler-Stevenson W.G., Liu F.T., Sobel M.E., Castronovo V. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J Cancer. 52:(4):1992;653-657.
36. Sillem M., Prifti S., Koumouridis A., Runnebaum B. Invasiveness corresponds to differentiation rather than to proteinase secretion in endometrial cancer cell lines. Eur J Gynaecol Oncol. 20:(5-6):1999;367-370.
37. Fukuda K., Mori M., Uchiyama M., Iwai K., Iwasaka T., Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol. 69:(3):1998;220-225.
38. Meyer M.E., Quirin-Stricker C., Lerouge T., Bocquel M.T., Gronemeyer H. A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms. J Biol Chem. 267:(15):1992;10882-10887.
39. Kazmi S.M., Visconti V., Plante R.K., Ishaque A., Lau C. Differential regulation of human progesterone receptor A and B form - mediated transactivation by phosphorylation. Endocrinology. 133:(3):1993;1230-1238.